Avalo Therapeutics NASDAQ:AVTX disclosed that its Chief Medical Officer, Doyle Mittie, completed a sale of common stock on April 6, 2026. Mittie disposed of 3,970 shares for an aggregate of approximately $71,508, with individual sale prices ranging from $18.00 to $18.10 per share.
On the same date, Mittie exercised stock options to acquire 3,970 shares of Avalo common stock at an exercise price of $12.65 per share. The total cost to acquire those optioned shares was $50,220.
Following the paired transactions - the option exercise and subsequent sale - Mittie now directly holds 3,622 shares of the company. The transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Mittie adopted on November 13, 2025.
Market movement since the transaction has been notable. The stock traded at $14.41 at the time of reporting, down from the sale prices but still showing a nearly 190% increase over the past 12 months, per InvestingPro data.
Analyst and program updates
Investor interest in Avalo’s development pipeline has been reflected in several recent analyst moves. Guggenheim reiterated its Buy rating on the company and set a $50 price target following Avalo’s fiscal year 2025 earnings announcement. In related operational news, the company confirmed that its Phase II LOTUS study of abdakibart for hidradenitis suppurativa remains on track, with data expected in the second quarter of 2026.
Coverage changes and target revisions also occurred across other firms. Citizens initiated coverage with a Market Outperform rating and a $52 price target. H.C. Wainwright raised its price target to $40 from $25 while maintaining a Buy rating, citing increased confidence in the AVTX-009 candidate. BTIG reiterated a Buy rating with a $40 target, noting the focus on the forthcoming Phase II trial data. TD Cowen also maintained a Buy rating, pointing to the potential of the Phase II opportunity.
Collectively, these analyst actions underscore sustained attention on Avalo’s clinical programs and investor interest tied to upcoming clinical readouts.
Note: The account details, option exercise, share counts, plan adoption date, analyst ratings, price targets, and program timing are reported as disclosed. No additional assumptions or projections are made beyond the disclosed items.